2 Pekeris Street
115 articles about CollPlant
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant
CollPlant Biotechnologies and United Therapeutics Corporation announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a second lifesaving organ, human kidneys.
CollPlant Biotechnologies Signs Distribution Agreement for its Vergenix Flowable Gel Product in the Commonwealth of Independent States (CIS)
CollPlant has already received first order amounting to hundreds of thousands of U.S. dollars Product distribution in six CIS countries expected to increase clinical use in new patient popu
CollPlant Biotechnologies to Present at Science of Aging Virtual Symposium 2020 During Healthy Aging Month
CollPlant's photocurable regenerative filler combines the advantages of collagen and hyaluronic acid for skin regeneration
CollPlant, a regenerative and aesthetics medicine company, announced financial results for the second quarter ended June 30, 2020 and provided an update on the Company's business developments.
CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures"
Collplant to Host Webinar Highlighting its Plant-based, Human Recombinant Collagen (rhCollagen) Platform for the Future of Aesthetic and Regenerative Medicine
CollPlant, a regenerative and aesthetics medicine company, announced that it will be hosting a webinar on Tuesday, May 12, 2020 at 11 am EDT/6 pm IDT that will feature its Co-Founder and Chief Scientist, Professor Oded Shoseyov and Chief Executive Officer, Mr. Yehiel Tal.
CollPlant, a regenerative and aesthetic medicine company, announced the launch of its updated corporate website.
CollPlant, a regenerative medicine company, announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute.
CollPlant, a regenerative medicine company, announced that Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, has issued a Letter to Shareholders, the full text of which follows below.
CollPlant, a regenerative medicine company, announced financial results for the third quarter ended September 30, 2019 and provided an update on the Company's business developments.
CollPlant CEO Yehiel Tal Appointed to Serve on International Society for Biofabrication's Industry Relations Committee
The Industry Relations Committee represents all aspects of Biofabrication including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization
CollPlant, a regenerative medicine company, announced financial results for the second quarter ended June 30, 2019 and provided an update on the Company's business developments.
Includes $3.5M from group of U.S. accredited investors with deep expertise in 3D printing
CollPlant Biotechnologies to Present at the 21st Annual Rodman & Renshaw Global Investment Conference
CollPlant announced that Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Tuesday, September 10th, 2019 at 1:45 pm EDT.
Investors include CollPlant's largest shareholder and U.S. tech investors
CollPlant, a regenerative medicine company, announced that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes.
Clinical Results From CollPlant's Advanced Wound Care Product VergenixFG to Be Presented at European Wound Management Association Conference
CollPlant, a regenerative medicine company, announced that the results from a clinical study conducted with its VergenixFG advanced wound care product will be presented at the 29th Conference of the European Wound Management Association.
CollPlant announced financial results for the first quarter ended March 31, 2019 and provided an update on the Company's business developments.
CollPlant Presents Its rhCollagen-based BioInks for 3D Bioprinting of Tissues and Organs at TERMIS Annual Meeting in Rhodes, Greece
CollPlant announced that Dr. Nadav Orr, presented the utilization of CollPlant's recombinant human collagen (rhCollagen) in the field of 3D Bioprinting tissues and organs at the Annual Meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) European Union Chapter in Rhodes, Greece on Monday, May 27, 2019.
CollPlant, a regenerative medicine company, has launched a new HQ and R&D center in Israel.